Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-006954.pdf
0001415889-24-006954.rtf
0001415889-24-006954.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007007.pdf
0001415889-24-007007.rtf
0001415889-24-007007.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007015.pdf
0001415889-24-007015.rtf
0001415889-24-007015.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007009.pdf
0001415889-24-007009.rtf
0001415889-24-007009.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007011.pdf
0001415889-24-007011.rtf
0001415889-24-007011.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007010.pdf
0001415889-24-007010.rtf
0001415889-24-007010.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007018.pdf
0001415889-24-007018.rtf
0001415889-24-007018.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007016.pdf
0001415889-24-007016.rtf
0001415889-24-007016.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007024.pdf
0001415889-24-007024.rtf
0001415889-24-007024.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007021.pdf
0001415889-24-007021.rtf
0001415889-24-007021.xls